Is Robotic Surgery Safe in Older Patients With Lung Cancer?
Robotic-assisted thoracic surgery (RATS) was safe in patients aged 80 years or older with lung cancer and demonstrated comparable postoperative outcomes to younger patients, a retrospective study found. After propensity score matching, researchers found no significant differences in complications, hospital stay duration, and 90-day mortality between the two age groups.
METHODOLOGY:
Researchers conducted a retrospective analysis of 340 patients who underwent major lung resections using RATS between 2015 and 2022 in Italy.
They divided patients into very elderly patients (VEPs; ≥ 80 years; n = 28) and non-elderly patients (NEPs; < 80 years; n = 312). Patients were characterised according to demographic variables, comorbidities, forced expiratory volume in 1 second (FEV1), and clinical and pathological stage.
Propensity score matching at a 1:3 ratio was performed to balance the two groups, resulting in 26 VEPs and 71 NEPs, using clinically relevant variables that were significantly different at baseline.
The primary endpoint was the assessment of complications; secondary endpoints were the comparison of the complications according to the Clavien-Dindo classification, postoperative stay, and mortality rate between VEP and NEP groups.
TAKEAWAY:
After propensity matching, complication rates did not differ significantly between VEP and NEP groups (46.2% vs 32.4%; P = .21).
The mean hospital stay was 4 days for both age groups (P = .85), and the 90-day mortality was low and not significantly different between VEP and NEP groups (3.9% vs 0%).
Pathological stage I disease was associated with a lower risk for complications (odds ratio [OR], 0.23; P = .006), and lobectomy was linked to a decreased risk for complications (OR, 0.29; P = .033); however, FEV1 continued to demonstrate a protective effect (OR, 0.97; P = .025).
IN PRACTICE:
"This study provides strong evidence supporting the safety and feasibility of RATS in patients aged 80 years and older, demonstrating comparable postoperative outcomes to younger patients after propensity score matching. FEV1, smoking history, and ASA [American Society of Anesthesiologists] score were the most significant predictors of postoperative complications, while age itself was not an independent risk factor," the authors of the study wrote.
SOURCE:
This study was led by Pierluigi Novellis, IRCCS San Raffaele Scientific Institute, Milan, Italy. It was published online on June 17, 2025, in the Journal of Clinical Medicine.
LIMITATIONS:
This study was limited by the retrospective nature of the analysis and the difference in the sample size between the two groups.
DISCLOSURES:
This study did not receive any external funding. Several authors reported receiving honoraria or having other ties with various sources.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
ChristianaCare opens neighborhood hospital in Chester County, Pennsylvania
ChristianaCare is opening its first neighborhood hospital in the company's 188-year history over the Delaware line northwest of Hockessin in Chester County, Pennsylvania. ChristianaCare Hospital, West Grove, is scheduled to open in mid-August at 1015 W. Baltimore Pike, West Grove, offering a new model of emergency and acute care in a modern, easy-to-access setting. The 20,000-square-foot hospital will be open 24 hours a day, seven days a week. Developed in partnership with Emerus Holdings Inc., the nation's leading developer of neighborhood hospitals, this facility will be staffed with board-certified emergency physicians, skilled nurses and clinical specialists. 'It's an honor and privilege to expand access to high-quality care for our neighbors in southern Chester County,' said Janice Nevin, president and CEO of ChristianaCare, in a press release. 'We will be opening our doors for the families in this community with a steadfast commitment to being their trusted health care partner. We're grateful for the opportunity to bring love and excellence to those we will serve.' Nevin said the project has received strong local support and was made possible in part by generous grants from the Commonwealth of Pennsylvania and the Chester County Board of Commissioners – Josh Maxwell, Marian Moskowitz and Eric Roe – whose leadership helped bring this vision to life. ChristianaCare Hospital, West Grove, is designed to meet a wide range of everyday medical needs with: A full-service emergency department with 10 treatment rooms. A 10-bed inpatient unit for overnight stays, observation and diagnostics. Advanced imaging and lab services, including ultrasound, CT scan and X-ray. Virtual access to specialists in such areas as cardiology, critical care and infectious disease. The emergency department is equipped to treat conditions such as falls, injuries, heart attacks and strokes. Patients requiring surgery or more complex care will be stabilized and transferred to a hospital with more expanded service offerings based on the clinical needs of the patient. 'This neighborhood hospital brings the right mix of services to support the health and well-being of our neighbors,' said Pauline Corso, president of ambulatory network continuity and growth at ChristianaCare. 'We're excited to bring care close to home to meet the needs of the community. We're here to stay and grow alongside this community.' As part of its long-term investment in the West Grove Campus, ChristianaCare has also purchased the building at 900 W. Baltimore Pike, across the street from the hospital. This facility houses a ChristianaCare primary care practice and imaging services, offering walk-in X-rays and scheduled mammography and ultrasound appointments. This health center will continue to evolve to meet the growing needs of the community, Nevin said. More hospital news: What Medicaid, Medicare cuts could mean for Delaware's hospitals, especially in rural areas More expansion plans in southeastern Pennsylvania ChristianaCare is expanding its neighborhood hospital model to address care gaps across southeastern Pennsylvania, Nevin said. New hospitals are being planned for Aston and Springfield Townships in Delaware County, with the Aston location under construction and expected to open in late 2026. In addition, ChristianaCare was the successful bidder for Crozer Health outpatient centers in Glen Mills, Havertown, Broomall and Media, further strengthening its regional footprint and ability to deliver timely, high-quality care. More on Crozer Health ChristianaCare to take on 5 Crozer Health outpatient locations with $50M bid History of care in southeastern Pennsylvania and Delaware ChristianaCare's presence in southeastern Pennsylvania is long-standing. The organization provides primary care at three Chester County locations – Kennett Square, Jennersville and West Grove – and recently opened a cardiology practice in West Grove. In neighboring Delaware County, the Concord Health Center in Chadds Ford offers a wide range of services, including primary care, women's health, sports medicine and behavioral health. Together, these sites serve as the medical home for more than 25,000 residents, underscoring ChristianaCare's deep commitment to delivering accessible, high-quality care where it's needed most, Nevin said. Headquartered in Wilmington, Delaware, ChristianaCare also has a network of primary care and outpatient services, home health care, urgent care centers, four hospitals with a total of 1,440 beds, a freestanding emergency department, a level-one trauma center and a level-three neonatal intensive care unit, a comprehensive stroke center, the Gene Editing Institute and regional centers of excellence in heart and vascular care, cancer care and women's health. Reporter Ben Mace covers real estate, development and business news. Reach him at rmace@ This article originally appeared on Delaware News Journal: ChristianaCare opens neighborhood hospital in southeastern Pennsylvania Solve the daily Crossword
Yahoo
31 minutes ago
- Yahoo
NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation
GLASSBORO, N.J., July 25, 2025--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey's innovation economy—with Garden State Venture Partners (GSVP) emerging as a key catalyst behind both. 1. MedTech Strategic Innovation Centers Backed by GSVP & NJEDA On July 21, NJEDA and Rowan University unveiled a major initiative to launch a Strategic Innovation Center, with locations in Camden and Mullica Hill, supporting early-stage medical technology companies with critical lab space, mentorship, and commercialization resources. GSVP, a New Jersey-based venture firm committed to fueling statewide innovation, is helping to make this possible through venture capital funding for early-stage medtech companies. Read release 2. A First-of-Its-Kind Maternal and Infant Health Innovation Center in Trenton Just one day later, Governor Murphy and First Lady Tammy Murphy broke ground on a Trenton-based center dedicated to maternal and infant health equity. The MedTech Strategic Innovation Center will also have a presence at the Maternal and Infant Health Innovation Center, which will focus on medical technologies that address racial disparities in care. Once again, GSVP will play a central role in helping bridge the gap between public health needs and private-sector innovation by accelerating promising, equity-driven health tech ventures. Read release Together, these initiatives represent over $100 million in coordinated investment, a model of public-private partnership, and a strategic bet on New Jersey as the next national hub for health tech and equity-focused innovation. GSVP's leadership and capital are essential to making that vision real. About Garden State Venture Partners Garden State Venture Partners (GSVP) is a next-gen venture capital firm built to attract and retain companies and talent within the state of New Jersey. GSVP is uniquely positioned to deepen existing partnerships and forge new ones across the state—catalyzing innovation and driving sustained economic success by connecting and investing in the state's innovation ecosystem. Learn more about GSVP at and access full leadership team bios here. View source version on Contacts Media Contact:Colleen Kendrick, CEONonprofit Partnersckendrick@ 1-800-298-9812 ext. 1
Medscape
32 minutes ago
- Medscape
Alternative Funders and Costly Meds: Are Patients Insured?
In the ever-evolving landscape of employer self-funded healthcare, cost-saving strategies emerge with promises of efficiency and reduced spending. Yet, for real patients — especially those battling chronic illnesses such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease — these quick-fix schemes can have devastating, unintended consequences. Among the most disruptive of these strategies in employer-funded health plans is the involvement of alternative funders: third-party entities inserted between patients and their essential therapies. Real patient stories most powerfully illustrate the physical, emotional, and financial harm they experience. Self-Insured Employers and Alternative Funder Programs Rising healthcare costs have led many employers to seek new ways to manage the growing expenses of self-insured health plans. Strategies such as alternative funder programs (AFPs) have been touted as ways to keep costs down and preserve financial stability for businesses. While these methods might give some relief to employer balance sheets, they can cause medication access delays and disruption, as well as added complexity, confusion, and stress for the patient. Madelaine (Mattie) A. Feldman, MD Essentially, AFPs contract with the employer to stop all coverage of the cost of expensive medicines, which includes most, if not all, of the biologic drugs. The AFPs will then apply for patient assistance from manufacturers and other programs under the guise of the patient being 'uninsured.' If assistance is obtained (free drug or copay cards), they will charge the employer a percentage of the price of the drug or card. Most manufacturer assistance programs have put up guardrails to prevent what they consider to be abuse of programs meant to help the truly 'uninsured.' If AFPs are unable to obtain free drugs, then they may try to source the medicine from outside of the United States, which manufacturers say is illegal. All of this creates delays in processing with denials and disruption of care for those relying on these specialty drugs. Employees are told they need to sign up for these programs or they may be responsible for the entire price of their medication, which often scares them into signing up, potentially giving the AFP years of access to very personal data. The Patient's Ordeal: When Savings Come Before Care Janelle Zeihen was diagnosed with Crohn's disease on February 14, 2022. Her diagnosis was delayed because her symptoms were initially mistaken for complications from recent pelvic radiation for cancer. Once properly identified, her gastroenterologist started her on vedolizumab (Entyvio, Takeda) infusions every 8 weeks and daily prednisone. This stabilized her condition, allowing her to eventually taper off prednisone. In January 2024, Zeihen's employer, Bedrock Healthcare, changed health insurance plans. She was told that vedolizumab would be covered only if she switched to home infusions via CVS's Coram home infusion service. Her disease remained controlled, but by August of that year, complications began when she was told her treatments would no longer be covered. Additionally, her gastroenterologist told her that she had been billed over $80,000 per infusion by Coram for the three infusions she had so far received in 2024, totaling $250,000. (In comparison, Medicare rates are only about $6500 per infusion.) This is when Zeihen's bureaucratic nightmare began. A nurse at the gastrointestinal doctor's office had worked with a certain rheumatology office manager and patient advocate, Nilsa Cruz, on difficult approvals for her patients in the past. She contacted Cruz to see if she could help to unravel the situation and hopefully get coverage for Zeihen to resume infusions at the rheumatologist's office. Cruz had many questions. Why was Zeihen supposedly covered for home infusion and then not covered? Why was she billed for three infusions that had already taken place? Did she have insurance or didn't she? Cruz spent more than 60 hours over 3 weeks reviewing paperwork, contacting insurances and third-party administrators, and spending time with Zeihen on her employer's employee/patient portal. She discovered that while Zeihen's insurance card listed Anthem, the plan was actually managed by Leading Edge Administrators, with provider-administered drug coverage handed over to Payer Matrix, an alternative funder. Cruz said that is when her 'heart sank.' She knew AFPs disrupted patient care and 'abused' patient assistance programs, resulting in many patients losing total access to treatments. Cruz found out after speaking with Anthem that they had mistakenly approved the home infusions in January 2024, but they were not actually responsible for administering or covering any costs to the plan. The company that Anthem was using to manage Zeihen's insurance plan, Leading Edge, had itself hired the AFP Payer Matrix to manage provider-administered drug coverage. Payer Matrix instructed Zeihen's employer, Bedrock, to exclude expensive biologics like vedolizumab from coverage. A Payer Matrix representative asked Cruz to apply for assistance from vedolizumab's manufacturer, Takeda, but Cruz said that she was obligated to tell Takeda that Payer Matrix was involved. Takeda denied the patient assistance request, suspecting improper use of their program for insured patients. Payer Matrix's nurse suggested to Zeihen that she change her medication to one from a different manufacturer from whom they may be able to get free drug. Zeihen was shocked that this 'insurance nurse' was trying to treat her without input from her gastroenterologist and she refused to agree to that. Cruz then went to Zeihen's employer for help, but the employer never responded to appeals or letters of medical necessity. Federal and state legislators/regulators and the Department of Labor were all copied on the communication. By now, Zeihen was left with overdue bills and denied treatments and no clear path to continue her medically necessary care. After persistent advocacy from Cruz, including contacting all involved parties, Anthem — who was not responsible for the coverage — agreed to cover all the vedolizumab infusions that Zeihen had received thus far in 2024 through Coram home infusion, as well as the next two scheduled treatments at the rheumatologist's office until the end of the year. This intervention relieved Zeihen from the $250,000 debt and allowed her to complete her treatment for the year. Where is Zeihen now? She was forced to leave her employer-covered insurance because the AFP in the plan had left her uninsured for the treatment that had been covered previously. She signed up for an exchange insurance plan, but her employer refused to cover any of the new exchange policy premiums, which were higher than her previous cost share. Ultimately, this resulted in her having to leave the full-time position with her employer. She now works part time and even though she lost many of the benefits of full-time employment, her Crohn's disease treatments are covered and the flares of her disease have subsided. She's not sure if her disease is better controlled because she is now getting her treatments in a timely manner or the fact that the stress, fear, and confusion caused by the AFP in her employer's plan is now gone. Why Employers Should Beware While pitched as a quick fix, AFPs may actually undermine employer goals in the long run. The administrative chaos can result in delayed or denied care, higher absenteeism, lost productivity, and even legal challenges if employees are saddled with unexpected medical debt. In addition, employers have a fiduciary duty to employees to prevent these costly arrangements that can cause psychological harm to employees. Furthermore, these programs can expose employers to reputational risk as stories of harmed workers spread. Zeihen's journey is emblematic of a growing problem in employer health benefits. The lure of immediate savings from AFPs often comes at an unacceptable cost to both employees and the organizations that depend on them. This story also displays the need for advocates like Cruz. Her dedication to patients and their well-being is exemplified in her perseverance and tenacity in finding a way to help Zeihen get the care she needed. I wish there were more 'Nilsa Cruzs' in this world. At the Coalition of State Rheumatology Organizations, we are fortunate to have the actual Nilsa Cruz in this story as part of our Payer Issue Response Team (PIRT). PIRT reviews 'payer' problems that are sent to us by rheumatologists around the country, and we do what we can to help solve them. While we can't solve every payer problem there is, we are grateful to be able to help those patients whose problems we can solve.
